Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-ACN376
- Development stage
- Unknown
- Lead developer
- Peking University Cancer Hospital & Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
68Ga-ACN376 is a gallium-68 labeled radiopharmaceutical imaging agent developed by Peking University Cancer Hospital & Institute. It consists of a single-domain antibody (nanobody), ACN376, which specifically targets the claudin-18 isoform 2 (CLDN18.2) protein. CLDN18.2 is a tight junction protein frequently overexpressed in various solid tumors, particularly gastric, esophageal, and pancreatic cancers, while remaining largely absent in healthy tissues. The nanobody is conjugated to the chelator NOTA and labeled with the positron-emitting isotope gallium-68 for use in PET/CT imaging. This agent is designed to non-invasively assess CLDN18.2 expression levels in vivo, serving as a companion diagnostic to identify patients likely to benefit from CLDN18.2-targeted therapies. Due to its small molecular size (approximately 15 kDa), 68Ga-ACN376 exhibits rapid blood clearance and high tumor penetration, allowing for same-day imaging.
- Other names
- 68Ga-NOTA-ACN376Gallium-68 ACN376Gallium68 ACN376Gallium 68 ACN376
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on 68Ga-ACN376.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-ACN376.